President Donald Trump has directed his administration to speed up reviews of certain psychedelic drugs, including ibogaine.

The order instructs the FDA to expedite review of drugs such as ibogaine, a drug that veterans' groups have said can help treat post-traumatic stress disorder.

By Kamal Choudhury April 20 (Reuters) - Shares of psychedelic drug developers rose on Monday after U.S. President Donald ...

Order calls on federal government to relax restrictions on psychedelics, including ibogaine, for potential treatments.

Trump ordered faster approval of ibogaine for PTSD, backing research and funding that could expand access to psychedelic-based treatments.

President Donald Trump signed an executive order that directs the FDA to accelerate their review of "psychedelics already designated as breakthrough therapy drugs." ...

The White House is in for a trip.

Executive order to speed access to psychedelic treatments likely to have limited legal impact despite high-profile push ...

Psychedelic drug ibogaine moves toward faster approval as a mental health treatment, backed by new policy support, while concerns remain over serious health risks.

Rochester, N.Y. (WHAM) — President Donald Trump last week signed an executive order directing federal regulators to fast-track the review of various psychedelic drugs that can be used in treating post ...